Serina Therapeutics, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Serina Therapeutics, Inc. (SER) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$10.52 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2023-03-31
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$10.52M.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was $1.00K.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was $1.00K, a 0.00% change year-over-year.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$10.52M.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2021 was -$8.58M, a 171740.00% decline from fiscal 2020.
- Serina Therapeutics, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2020 was $5.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | -$10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$10.52M derived: sum of 2 quarters · filed 2023-03-31 | -$10.52M derived: sum of 3 quarters · filed 2023-03-31 | -$10.52M 10-K · filed 2023-03-31 | |
| 2022-09-30 | $1.00K 10-Q · filed 2022-11-10 | $1.00K derived: sum of 2 quarters · filed 2022-11-10 | $2.00K 10-Q · filed 2022-11-10 | -$8.58M derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.00K 10-Q · filed 2022-08-12 | -$8.58M derived: sum of 3 quarters · filed 2023-03-31 | -$8.58M derived: sum of 4 quarters · filed 2023-03-31 | |
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-13 | -$8.58M derived: sum of 2 quarters · filed 2023-03-31 | -$8.58M derived: sum of 3 quarters · filed 2023-03-31 | -$8.58M derived: sum of 4 quarters · filed 2023-03-31 | |
| 2021-12-31 | -$8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$8.58M derived: sum of 2 quarters · filed 2023-03-31 | -$8.58M derived: sum of 3 quarters · filed 2023-03-31 | -$8.58M 10-K · filed 2023-03-31 | $3.00K 10-K · filed 2022-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.00K derived: sum of 2 quarters · filed 2022-11-10 | $2.00K 10-Q · filed 2022-11-10 | $4.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-12 | $2.00K 10-Q · filed 2022-08-12 | $4.00K derived: sum of 3 quarters · filed 2022-08-12 | $6.00K derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-13 | $3.00K derived: sum of 2 quarters · filed 2022-05-13 | $5.00K derived: sum of 3 quarters · filed 2022-05-13 | $6.00K derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $4.00K derived: sum of 2 quarters · filed 2022-03-29 | $5.00K derived: sum of 3 quarters · filed 2022-03-29 | $5.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $2.00K 10-Q · filed 2021-11-12 | $3.00K derived: sum of 2 quarters · filed 2021-11-12 | $3.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $1.00K 10-Q · filed 2021-08-13 | $1.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |